Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis-Reference-Cited by-同舟云学术

Health care utilization and cost associated with switching biologics within the first year of biologic treatment initiation among patients with ankylosing spondylitis

Published:2021-01 Issue:1 Volume:27 Page:27-36
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Yi Esther¹,Dai Dong¹,Piao Olivia W²,Zheng Josh Z²,Park Yujin¹

Affiliation:

1. Novartis Pharmaceuticals Corporation, East Hanover, NJ.

2. KMK Consulting, East Hanover, NJ.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study;Rheumatology and Therapy;2024-08-20

2. Dose Tapering and Discontinuation of Biologic DMARDs in Axial Spondyloarthritis: A Narrative Review (2023 SPARTAN Annual Meeting Proceedings);Current Rheumatology Reports;2024-02-09

3. Association of health care utilization and costs with patient-reported outcomes in patients with ankylosing spondylitis;Journal of Managed Care & Specialty Pharmacy;2022-09

4. Health-Care and Societal Costs Associated with Non-Persistence with Subcutaneous TNF-α Inhibitors in the Treatment of Inflammatory Arthritis (IA): A Retrospective Observational Study;Advances in Therapy;2021-11-09

5. Patterns of mental health service use among Medicaid-insured youths treated by nurse practitioners and physicians: A retrospective cohort study;International Journal of Nursing Studies;2021-08